Edition:
United Kingdom

Merus NV (MRUS.OQ)

MRUS.OQ on NASDAQ Stock Exchange Global Market

19.00USD
21 Sep 2018
Change (% chg)

$-0.36 (-1.86%)
Prev Close
$19.36
Open
$19.69
Day's High
$19.69
Day's Low
$19.00
Volume
36,018
Avg. Vol
14,277
52-wk High
$26.49
52-wk Low
$14.24

Latest Key Developments (Source: Significant Developments)

Merus NV Posts Q1 Loss Per Share Eur 0.40
Thursday, 26 Jul 2018 

July 26 (Reuters) - Merus NV ::MERUS ANNOUNCES RECENT CORPORATE DEVELOPMENTS AND FINANCIAL RESULTS FOR THE FIRST QUARTER 2018.Q1 LOSS PER SHARE EUR 0.40.Q1 REVENUE EUR 9.9 MILLION VERSUS EUR 3.9 MILLION.Q1 REVENUE VIEW EUR 2.7 MILLION -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE VIEW EUR -0.74 -- THOMSON REUTERS I/B/E/S.EXPECTS THAT ITS EXISTING CASH, CASH EQUIVALENTS AND INVESTMENTS WILL BE SUFFICIENT TO FUND ITS OPERATIONS THROUGH END OF 2020.  Full Article

Merus Files Prospectus Relates To Proposed Resale Or Other Disposition Of Co's Shares By Selling Shareholders
Tuesday, 15 May 2018 

May 15 (Reuters) - Merus NV ::MERUS NV FILES PROSPECTUS RELATES TO PROPOSED RESALE OR OTHER DISPOSITION OF UP TO 3.1 MILLION OF CO'S COMMON SHARES BY SELLING SHAREHOLDERS - SEC FILING.  Full Article

Merus And Simcere Announce Strategic Collaboration On Multiple Bispecific Antibodies
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Simcere Pharmaceutical Group ::MERUS AND SIMCERE ANNOUNCE STRATEGIC COLLABORATION ON MULTIPLE BISPECIFIC ANTIBODIES.MERUS - AGREED TO GRANT SIMCERE EXCLUSIVE LICENSE TO DEVELOP & COMMERCIALIZE IN CHINA 3 BISPECIFIC ANTIBODIES USING CO'S BICLONICS TECHNOLOGY PLATFORM.MERUS NV- CO TO BE ELIGIBLE TO GET UPFRONT & MILESTONE PAYMENTS CONTINGENT UPON SIMCERE ACHIEVING CERTAIN SPECIFIED DEVELOPMENT & COMMERCIAL GOALS.MERUS NV - MERUS WILL BE ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS ON SALES OF ANY PRODUCTS RESULTING FROM COLLABORATION IN CHINA FROM SIMCERE.MERUS NV - SIMCERE WILL BE ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS ON SALES OUTSIDE OF CHINA FROM MERUS.MERUS NV - ADDITIONAL FINANCIAL DETAILS WERE NOT DISCLOSED UNDER COLLABORATION WITH SIMCERE.  Full Article

Merus Nv Q3 Loss Per Share Eur 0.81
Thursday, 30 Nov 2017 

Merus Nv ::MERUS ANNOUNCES THIRD QUARTER 2017 FINANCIAL RESULTS AND CLINICAL HIGHLIGHTS.Q3 LOSS PER SHARE EUR 0.81.Q3 REVENUE EUR 3.5 MILLION VERSUS EUR 1.2 MILLION.Q3 REVENUE VIEW EUR 2.2 MILLION -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW EUR -0.58 -- THOMSON REUTERS I/B/E/S.- ‍EXPECTS CURRENT CASH AND CASH EQUIVALENTS BALANCE TO BE SUFFICIENT TO FUND RESEARCH AND DEVELOPMENT PROGRAMS AND OPERATIONS WELL INTO 2019​.  Full Article

Aglaia Oncology Fund B.V. reports 6.9 percent passive stake in Merus Nv as of December 31, 2016
Friday, 10 Feb 2017 

Aglaia Oncology Fund B.V. :Aglaia Oncology Fund B.V. Reports a 6.9 percent passive stake in Merus Nv as of December 31, 2016 - SEC filing.  Full Article

BRIEF-Merus Q4 Loss Per Share EUR 0.73

* MERUS ANNOUNCES RECENT CORPORATE DEVELOPMENTS AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2017